GT Biopharma Inc

NASDAQ GTBP
$0.95 0.02 1.72%
Today share price
USA
Sector: Healthcare Industry: Biotechnology
Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free

Rating Finrange

Index: 15 %
Market cap Market capitalization – refers to the total value of all a company's shares of stock. It is calculated by multiplying the price of a stock by its total number of outstanding shares.
5.04M
EV Enterprise value is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. Enterprise value includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.
2.68M
Beta Beta is one of the most popular indicators of risk is a statistical measure. Analysts use this measure often when they need to determine a stock's risk profile.
-
Shares Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company’s insiders.
2.35M
YTD Year to date (YTD) refers to the period of time beginning the first day of the current calendar year or fiscal year up to the current date. he acronym often modifies concepts such as investment returns and price change.
-69.02 %

Upcoming events GT Biopharma Inc

All events
No upcoming events scheduled

Stock chart GT Biopharma Inc

Stock analysis GT Biopharma Inc

Indicator Company Industry
P/E (LTM) Shows how many years the investor's investment in the company will pay off with a profit over the last 12 months.
-0.43 -1.30
P/BV (LTM) Shows the ratio of the market price of the share to the current book value.
-3.46 1.15
EV/EBITDA (LTM) Represents the ratio of the company's value to its pre-tax EBITDA in the last 12 months.
-0.24 -0.75
Net Debt/EBITDA (LTM) A company's debt ratio, which indicates how long the company will need to run on cash flow in the past 12 months to pay off its own debt.
0.21 0.42
ROE (LTM) Shows the efficiency of using the share capital by the company. In other words, ROE shows how much of the company's net profit for the invested capital over the last 12 months.
1191.02 -50.00

Price change GT Biopharma Inc per year

0.90$ 3.80$
Min Max

Summary analysis GT Biopharma Inc

Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free

Shareholder structure GT Biopharma Inc

Revenue and net income GT Biopharma Inc

All parameters

About company GT Biopharma Inc

GT Biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. The company develops GTB-3650, which is in preclinical studies that target CD33 on the surface of myeloid leukemias and an agonistic camelid; GTB-5550 which targets B7-H3 on the surface of advanced solid tumors; GTB-7550, a product candidate in development for the treatment of lupus and other autoimmune disorders. GT Biopharma, Inc. entered a master services agreement with Cytovance Biologics, Inc. to perform biologic development and manufacturing services, and to produce and test compounds; and a license agreement with the Regents of the University of Minnesota to develop and commercialize cancer therapies using TriKE technology. The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was incorporated in 1965 and is based in Brisbane, California.
Address:
315 Montgomery Street, San Francisco, CA, United States, 94104
Company name: GT Biopharma Inc
Issuer ticker: GTBP
ISIN: US36254L2097
Country: USA
Exchange: NASDAQ
Currency: $
IPO date: 2017-09-22
Sector: Healthcare
Industry: Biotechnology
Site: https://www.gtbiopharma.com